308 related articles for article (PubMed ID: 9256140)
1. Human urinary macrophage colony-stimulating factor reduces the incidence and duration of febrile neutropenia and shortens the period required to finish three courses of intensive consolidation therapy in acute myeloid leukemia: a double-blind controlled study.
Ohno R; Miyawaki S; Hatake K; Kuriyama K; Saito K; Kanamaru A; Kobayashi T; Kodera Y; Nishikawa K; Matsuda S; Yamada O; Omoto E; Takeyama H; Tsukuda K; Asou N; Tanimoto M; Shiozaki H; Tomonaga M; Masaoka T; Miura Y; Takaku F; Ohashi Y; Motoyoshi K
J Clin Oncol; 1997 Aug; 15(8):2954-65. PubMed ID: 9256140
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of a new formulation of lenograstim (recombinant glycosylated human granulocyte colony-stimulating factor) containing gelatin for the treatment of neutropenia after consolidation chemotherapy in patients with acute myeloid leukemia.
Takeshita A; Saito H; Toyama K; Horiuchi A; Kuriya S; Furusawa S; Tsuruoka N; Takiguchi T; Matsuda T; Utsumi M; Shiku H; Matsui T; Egami K; Tamura K; Ohno R
Int J Hematol; 2000 Feb; 71(2):136-43. PubMed ID: 10745623
[TBL] [Abstract][Full Text] [Related]
3. Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucémies Aigues Myeloblastiques.
Harousseau JL; Witz B; Lioure B; Hunault-Berger M; Desablens B; Delain M; Guilhot F; Le Prise PY; Abgrall JF; Deconinck E; Guyotat D; Vilque JP; Casassus P; Tournilhac O; Audhuy B; Solary E
J Clin Oncol; 2000 Feb; 18(4):780-7. PubMed ID: 10673519
[TBL] [Abstract][Full Text] [Related]
4. [A randomized double-blind controlled study of recombinant human granulocyte colony-stimulating factor in patients with neutropenia induced by consolidation chemotherapy for acute myeloid leukemia. (rG.CSF clinical study group)].
Takeshita A; Ohno R; Hirashima K; Toyama K; Okuma M; Saito H; Ikeda Y; Tomonaga M; Asano S
Rinsho Ketsueki; 1995 Jun; 36(6):606-14. PubMed ID: 7543956
[TBL] [Abstract][Full Text] [Related]
5. Lack of benefit of granulocyte macrophage or granulocyte colony stimulating factor in patients with febrile neutropenia.
Siddiqui T; Burney IA; Kakepoto GN; Khurshid M; Salam A; Smego RA
J Pak Med Assoc; 2002 May; 52(5):206-10. PubMed ID: 12174492
[TBL] [Abstract][Full Text] [Related]
6. A randomized controlled study of granulocyte colony stimulating factor after intensive induction and consolidation therapy in patients with acute lymphoblastic leukemia. Japan Adult Leukemia Study Group.
Ohno R; Tomonaga M; Ohshima T; Masaoka T; Asou N; Oh H; Nishikawa K; Kanamaru A; Murakami H; Furusawa S
Int J Hematol; 1993 Aug; 58(1-2):73-81. PubMed ID: 7693029
[TBL] [Abstract][Full Text] [Related]
7. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia.
Vellenga E; Uyl-de Groot CA; de Wit R; Keizer HJ; Löwenberg B; ten Haaft MA; de Witte TJ; Verhagen CA; Stoter GJ; Rutten FF; Mulder NH; Smid WM; de Vries EG
J Clin Oncol; 1996 Feb; 14(2):619-27. PubMed ID: 8636779
[TBL] [Abstract][Full Text] [Related]
8. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111.
Larson RA; Dodge RK; Linker CA; Stone RM; Powell BL; Lee EJ; Schulman P; Davey FR; Frankel SR; Bloomfield CD; George SL; Schiffer CA
Blood; 1998 Sep; 92(5):1556-64. PubMed ID: 9716583
[TBL] [Abstract][Full Text] [Related]
9. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
Creutzig U; Zimmermann M; Lehrnbecher T; Graf N; Hermann J; Niemeyer CM; Reiter A; Ritter J; Dworzak M; Stary J; Reinhardt D
J Clin Oncol; 2006 Sep; 24(27):4499-506. PubMed ID: 16983120
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of granulocyte and granulocyte-macrophage colony-stimulating factors in the induction treatment of adult acute lymphoblastic leukemia: a multicenter randomized study.
Thomas X; Boiron JM; Huguet F; Reman O; Sutton L; Turlure P; Garban F; Gardin C; Espinouse D; Boulat O; Lhéritier V; Fiere D;
Hematol J; 2004; 5(5):384-94. PubMed ID: 15448664
[TBL] [Abstract][Full Text] [Related]
11. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating-factor support for dose-intensive cyclophosphamide, etoposide, and cisplatin.
Yau JC; Neidhart JA; Triozzi P; Verma S; Nemunaitis J; Quick DP; Mayernik DG; Oette DH; Haynes FA; Holcenberg J
Am J Hematol; 1996 Apr; 51(4):289-95. PubMed ID: 8602629
[TBL] [Abstract][Full Text] [Related]
12. Neutropenia-associated outcomes in adults with acute myeloid leukemia receiving cytarabine consolidation chemotherapy with or without granulocyte colony-stimulating factor.
Bradley AM; Deal AM; Buie LW; van Deventer H
Pharmacotherapy; 2012 Dec; 32(12):1070-7. PubMed ID: 23208834
[TBL] [Abstract][Full Text] [Related]
13. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490).
Rowe JM; Andersen JW; Mazza JJ; Bennett JM; Paietta E; Hayes FA; Oette D; Cassileth PA; Stadtmauer EA; Wiernik PH
Blood; 1995 Jul; 86(2):457-62. PubMed ID: 7605984
[TBL] [Abstract][Full Text] [Related]
14. Macrophage colony-stimulating factor for cancer therapy.
Motoyoshi K
Oncology; 1994; 51(2):198-204. PubMed ID: 8196902
[TBL] [Abstract][Full Text] [Related]
15. Biological activities and clinical application of M-CSF.
Motoyoshi K
Int J Hematol; 1998 Feb; 67(2):109-22. PubMed ID: 9631577
[TBL] [Abstract][Full Text] [Related]
16. Post-remission intensive consolidation with high-dose cytarabine-based chemotherapy and granulocyte colony-stimulatory factor in adults with acute myelogenous leukemia: a preliminary report.
Hsu HC; Chiu CF; Tan TD; Chau WK; Tseng CS; Ho CH
Zhonghua Yi Xue Za Zhi (Taipei); 1995 Nov; 56(5):305-11. PubMed ID: 8605644
[TBL] [Abstract][Full Text] [Related]
17. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial.
Ravaud A; Chevreau C; Cany L; Houyau P; Dohollou N; Roché H; Soubeyran P; Bonichon F; Mihura J; Eghbali H; Tabah I; Bui BN
J Clin Oncol; 1998 Sep; 16(9):2930-6. PubMed ID: 9738560
[TBL] [Abstract][Full Text] [Related]
18. Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022.
Moore JO; Dodge RK; Amrein PC; Kolitz J; Lee EJ; Powell B; Godfrey S; Robert F; Schiffer CA
Blood; 1997 Feb; 89(3):780-8. PubMed ID: 9028308
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials.
Sung L; Nathan PC; Lange B; Beyene J; Buchanan GR
J Clin Oncol; 2004 Aug; 22(16):3350-6. PubMed ID: 15310780
[TBL] [Abstract][Full Text] [Related]
20. Outpatient consolidation chemotherapy in pediatric acute myeloid leukemia: a retrospective analysis.
Bakhshi S; Singh P; Swaroop C
Hematology; 2009 Oct; 14(5):255-60. PubMed ID: 19843379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]